Company intelligence / Profile preview

RE Ventures I

Ownership: Private
Development stage: Other

Overview

RE Ventures I is a joint venture focused on early-stage drug discovery and development, specifically targeting ENPP1 for the treatment of hypophosphatasia with small molecule therapies. It is a collaboration between Exscientia and Rallybio under the RE Ventures structure, with Exscientia generally responsible for advancing candidates through preclinical studies[1][4].

Therapeutic areas: Rare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Exscientia/Rallybio

Beyond the preview

Go deeper on RE Ventures I.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RE Ventures I.

Explore the full profile